Comparative Pharmacology
Head-to-head clinical analysis: JENLOGA versus KELNOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENLOGA versus KELNOR.
JENLOGA vs KELNOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
Combined oral contraceptive; inhibits ovulation by suppressing gonadotropin release (FSH and LH) primarily via progestational activity; increases viscosity of cervical mucus to inhibit sperm penetration; alters endometrium.
350 mg orally once daily with food.
KELNOR (norethindrone acetate and ethinyl estradiol) is a combined oral contraceptive. Typical adult dose: 1 tablet (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 placebo tablets, starting on day 1 of menstrual cycle.
None Documented
None Documented
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Terminal elimination half-life 12-15 hours; clinically relevant for once-daily dosing.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive